Childhood Cancer Data Initiative Annual Symposium (Abstract Registration): Submission #76

serial: '76'
sid: '192391'
uuid: 315c3ecd-4d04-43e3-8d65-90f2993da697
uri: '/nci/ccdisymposium/abstract?utm_source=aug18_2025abstract&utm_medium=email&utm_campaign=2026ccdisymposium'
created: '1787771549'
completed: '1787771862'
changed: '1787771862'
in_draft: '0'
current_page: ''
remote_addr: 10.208.24.244
uid: '0'
langcode: en
webform_id: ccdi_symposium_abstract
entity_type: node
entity_id: '2139'
locked: '0'
sticky: '0'
notes: ''
metatag: meta
data:
  authors_:
    - add_author_degree: PharmD
      add_author_first_name: Min
      add_author_last_name: Kang
      add_author_middle: H
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: PhD
      add_author_first_name: In-Hyoung
      add_author_last_name: Yang
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: PhD
      add_author_first_name: Nighat
      add_author_last_name: Noureen
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: MS
      add_author_first_name: Kristyn
      add_author_last_name: McCoy
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: BS
      add_author_first_name: Jonas
      add_author_last_name: Nance
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: BS
      add_author_first_name: Diana
      add_author_last_name: Ixlamati-Nava
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: PhD
      add_author_first_name: Ashly
      add_author_last_name: Hindle
      add_author_middle: ''
      add_author_organization: 'Texas Tech University Health Sciences Center'
    - add_author_degree: MD
      add_author_first_name: Meredith
      add_author_last_name: Erwin
      add_author_middle: S
      add_author_organization: 'Hospital for Sick Children, University of Toronto'
    - add_author_degree: MD
      add_author_first_name: Michael
      add_author_last_name: Hogarty
      add_author_middle: D
      add_author_organization: "Children's Hospital of Philadelphia and University of Pennsylvania"
    - add_author_degree: 'MD, PhD'
      add_author_first_name: Charles
      add_author_last_name: Reynolds
      add_author_middle: P
      add_author_organization: 'Texas Tech University Health Sciences Center'
  abstract: 'Tumor biopsies are often not obtained at the time of progressive disease (PD) in neuroblastoma (NB).  Patient-derived xenografts (PDXs) established from bone marrow or blood of NB patients enable studies to define molecular mechanisms and approaches to overcome therapy resistance.  Tumor, marrow, or peripheral blood samples from 40 high-risk patients, 19 at diagnosis (Dx) and 21 at PD (12 of 21 at post-mortem), were received via Children’s Oncology Group (COG) protocol ANBL00B1 and established as PDXs.  PDXs were classified by the response to chemotherapy (Cyclo/Topo, cyclophosphamide + topotecan, 3 x 21-day cycles, or TMZ/IRI, relapse chemo, temozolomide + irinotecan, 2 x 21-day cycles) as non-responders (NR), stable disease (SD), partial responders (PR), and complete responders (CR).  Engraftment rates were 17% for Dx and 24% for PD samples. Based on an algorithm we developed for PDX response evaluation, Cyclo/Topo responses were NR (n=11), SD (n=2), PR (n=9), and CR (n=18), and 9 of 11 showed CR to TMZ/IRN.  Nine of 13 (69%) of the NR+SD PDXs were established from post-mortem PD (PD-PM) samples, while 12 of 18 (67%) of the CR group were from Dx samples. The response of PDXs to Cyclo/Topo was greater for pretherapy (Dx) PDXs than for PD-PM or PD PDXs; six of the 11 PD models showed significantly better EFS for TMZ/IRN relative to Cyclo/Topo (P<0.05, n=6 PDXs). This panel of 40 NB PDXs, characterized for their response to chemotherapy, will enable studies to define the molecular mechanisms of NB therapy resistance and is available at www.CCcells.org.  '
  abstract_title_: 'Characterizing the Children’s Oncology Group panel of neuroblastoma patient-derived xenografts for response to induction and salvage chemotherapy'
  email_address_: min.kang@ttuhsc.edu
  institution_: 'Texas Tech University Health Sciences Center'
  presenting_author_: 'Min H. Kang'